Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770. doi:10.1016/S0140-6736(16)32126-227914657
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease. Lancet. 2017;389:1741–1755. doi:10.1016/S0140-6736(16)31711-127914655
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. doi:10.1053/j.gastro.2008.09.01218854185
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group. N Engl J Med. 1997;337:1029–1035. doi:10.1056/NEJM1997100933715029321530
   PubMed Web of Science ®Google Scholar
• Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505. doi:10.1136/bmj.j250528630047
   PubMed Web of Science ®Google Scholar
• Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014;63:1607–1616. doi:10.1136/gutjnl-2013-30560724056767
   PubMed Web of Science ®Google Scholar
• Ma C, Moran GW, Benchimol EI, et al. Surgical rates for Crohn’s disease are decreasing: a population-based time trend analysis and validation study. Am J Gastroenterol. 2017;112:1840–1848. doi:10.1038/ajg.2017.39429087396
   PubMed Web of Science ®Google Scholar
• Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis. 2019;25:831–842. doi:10.1093/ibd/izy31330312391
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto Consensus. Inflamm Bowel Dis. 2019;25:1–13. doi:10.1093/ibd/izy24730099529
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384–413. doi:10.14309/ajg.000000000000015230840605
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen MJ, Leenders M, COIN Study Group and the Dutch Initiative on Crohn and Colitis, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 63;2014:72–79. doi:10.1136/gutjnl-2012-30337623135759
   PubMed Web of Science ®Google Scholar
• Raffals LE, Nguyen GC, Rubin DT. Switching between biologics and biosimilars in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2019;17:818–823. doi:10.1016/j.cgh.2018.08.06430196164
   PubMed Web of Science ®Google Scholar
• Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2017;33:2160–2172. doi:10.1007/s12325-016-0431-527798772
   PubMed Web of Science ®Google Scholar
• Kurki P, Ekman N. Biosimilar regulation in the EU. Expert Rev Clin Pharmacol. 2015;8(5):649–659. doi:10.1586/17512433.2015.107118826294076
   PubMed Web of Science ®Google Scholar
• Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–e509. doi:10.1016/S1470-2045(16)30374-627819248
   PubMed Web of Science ®Google Scholar
• Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974–982. doi:10.1136/annrheumdis-2016-20916626964144
   PubMed Web of Science ®Google Scholar
• Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). WHO Expert Committee on Biological Standardization, Sixtieth report. 19-23 10 2009 WHO Technical Report Series No. 977, 2013 - Annex 2. Vol 2013:34.
   Google Scholar
• European Medicines Agency. Flixabi information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/flixabi. Accessed 10 15, 2019.
   Google Scholar
• European Medicines Agency. Zessly information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zessly. Accessed 10 15, 2019.
   Google Scholar
• European Medicines Agency. Inflectra information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/inflectra. Accessed 1015, 2019..
   Google Scholar
• European Medicines Agency. Remsima information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remsima. Accessed 1015, 2019..
   Google Scholar
• European Medicines Agency. Imraldi information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi. Accessed 1015, 2019.
   Google Scholar
• European Medicines Agency. Amgevita information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita. Accessed 1015, 2019.
   Google Scholar
• European Medicines Agency. Hyrimoz information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz. Accessed 1015, 2019.
   Google Scholar
• European Medicines Agency. Cyltezo information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo. Accessed 1015, 2019.
   Google Scholar
• European Medicines Agency. Hulio information website. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hulio. Accessed 1015, 2019.
   Google Scholar
• Fiorino G, Caprioli F, Daperno M, National patients’ association representatives; IG-IBD members, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 51;2019:632–639. doi:10.1016/j.dld.2019.02.00430872085
   PubMedGoogle Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–1612. doi:10.1136/annrheumdis-2012-20309123687259
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613–1620. doi:10.1136/annrheumdis-2012-20309023687260
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lam G, Ma C, et al. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther. 2019;49:31–40. doi:10.1111/apt.1499730411382
   PubMed Web of Science ®Google Scholar
• Matsuno H, Matsubara T. A randomized double-blind parallel-group Phase III study to compare the efficacy and safety of NI-071 and infliximab reference product in Japanese patients with active rheumatoid arthritis refractory to methotrexate. Mod Rheumatol. 2018;2018:1–26.
   Google Scholar
• Kay J, Chopra A, Lassen C, et al. FRI0117 BOW015, a biosimilar Infliximab: disease activity and disability outcomes from a phase 3 active comparator study in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis. 2015;74:462–463.
   Google Scholar
• Meyer A, Rudant J, Drouin J, et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French equivalence study. Ann Intern Med. 2019;170:99–107. doi:10.7326/M18-151230534946
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. NOR-SWITCH Study Group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316. doi:10.1016/S0140-6736(17)30068-528502609
   PubMed Web of Science ®Google Scholar
• Goll GL, Jørgensen KK, Sexton J, et al. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med. 2019;285(6):653–669. doi:10.1111/joim.1288030762274
   PubMed Web of Science ®Google Scholar
• Khanna R, Zou G. Is a biosimilar interchangeable with an originator? Gastroenterology. 2017;153:1160–1162. doi:10.1053/j.gastro.2017.08.04928867270
   PubMedGoogle Scholar
• Sturm A, Maaser C, Calabrese E, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13:273–284. doi:10.1093/ecco-jcc/jjy11430137278
   PubMed Web of Science ®Google Scholar
• Khanna R, Zou G, Feagan BG. Evolution of the randomized controlled trial in inflammatory bowel disease: current challenges and future solutions. Inflamm Bowel Dis. 2018;24:2155–2164. doi:10.1093/ibd/izy11729788218
   PubMedGoogle Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699–1707. doi:10.1016/S0140-6736(18)32196-230929895
   PubMed Web of Science ®Google Scholar
• Gecse KB, D’Haens GR. Infliximab biosimilar CT-P13 in Crohn’s disease. Lancet. 2019;393:1671–1672. doi:10.1016/S0140-6736(18)32778-830929894
   PubMedGoogle Scholar
• Kay J, Schoels MM, Dörner T, et al. Task Force on the use of biosimilars to treat rheumatological diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77:165–174. doi:10.1136/annrheumdis-2017-21193728866648
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Buurman DJ, Sturkenboom MG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765–771. doi:10.1111/apt.1203022928581
   PubMedGoogle Scholar
• Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohnès and Colitis Organization. J Crohns Colitis. 2014;8:1548–1550. doi:10.1016/j.crohns.2014.06.00725008477
   PubMed Web of Science ®Google Scholar
• Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, SECURE study group, et al. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 3;2018:404–412. doi:10.1016/S2468-1253(18)30082-729606564
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132–1138. doi:10.1136/gutjnl-2015-30929025897019
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70:40–48. doi:10.1002/art.4033628950421
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis: fifty-two-week phase III randomized study results. Arthritis Rheumatol. 2018;70:832–840. doi:10.1002/art.v70.629439289
   PubMed Web of Science ®Google Scholar
• Norman P. Humira: the impending patent battles over adalimumab biosimilars. Pharm Pat Anal. 2016;5:141–145. doi:10.4155/ppa-2016-000227087201
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Biosimilar and interchangeable products: the U.S. FDA perspective. Available from: https://www.fda.gov/media/112818/download. Accessed 1015, 2019.
   Google Scholar
• US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product. Available from: https://www.fda.gov/media/124907/download. Accessed 1230, 2019 Accessed 10 15, 2019.
   Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179:623–631. doi:10.1111/bjd.1689029917226
   PubMed Web of Science ®Google Scholar
• Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22–31. doi:10.1038/nrgastro.2016.15527729659
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease–an update. J Crohns Colitis. 2017;11:26–34. doi:10.1093/ecco-jcc/jjw19827927718
   PubMed Web of Science ®Google Scholar
• Argüelles-Arias F, Barreiro-de-Acosta M, Carballo F, et al. Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig. 2013;105:37–43. doi:10.4321/S1130-0108201300010000623548008
   PubMed Web of Science ®Google Scholar
• Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124:3191–3196. doi:10.1182/blood-2014-06-58361725298038
   PubMed Web of Science ®Google Scholar
• Fiorino G, Gilardi D, Correale C, et al. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opin Biol Ther. 2019;19:1023–1030. doi:10.1080/14712598.2019.156403330601098
   PubMed Web of Science ®Google Scholar
• Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;2019:izz059.
   Google Scholar
• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–2778. doi:10.1016/S0140-6736(17)32448-029050646
   PubMed Web of Science ®Google Scholar
• Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47:364–370. doi:10.1111/apt.1443029164650
   PubMed Web of Science ®Google Scholar
• Yu B. Greater potential cost savings with biosimilar use. Am J Manag Care. 2016;22:378.27266439
   PubMed Web of Science ®Google Scholar
• Khan R, Nugent CM, Scaffidi MA, et al. Association of biologic prescribing for inflammatory bowel disease with industry payments to physicians. JAMA Intern Med. 2019. doi:10.1001/jamainternmed.2019.0999
   Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74:655–661. doi:10.1007/s00228-018-2418-429368188
   PubMed Web of Science ®Google Scholar
• Pouillon L, Socha M, Demore B, et al. The nocebo effect: a clinical challenge in the era of biosimilars. Expert Rev Clin Immunol. 2018;14:739–749. doi:10.1080/1744666X.2018.151240630118338
   PubMed Web of Science ®Google Scholar
• Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–1482. doi:10.1038/ajg.2012.26022929759
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767. doi:10.1038/ajg.2008.8819174781
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70:60–68. doi:10.1002/art.4032429045077
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Lönnfors S, Roblin X, et al. Patient perspectives on biosimilars: a survey by the European Federation of Crohn’s and Ulcerative Colitis Associations. J Crohns Colitis. 2017;11:128–133. doi:10.1093/ecco-jcc/jjw13827481878
   PubMed Web of Science ®Google Scholar
• Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J. 2013;89:540–546. doi:10.1136/postgradmedj-2012-13173023842213
   PubMed Web of Science ®Google Scholar
• Pouillon L, Danese S, Hart A, et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharmacol Ther. 2019;49:1181–1187. doi:10.1111/apt.1522330932219
   PubMed Web of Science ®Google Scholar
• Chavarria V, Vian J, Pereira C, et al. The placebo and nocebo phenomena: their clinical management and impact on treatment outcomes. Clin Ther. 2017;39:477–486. doi:10.1016/j.clinthera.2017.01.03128237673
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Biosimilar medicines website. Available from: https://www.nice.org.uk/advice/ktt15/resources/biosimilar-medicines-58757954414533. Accessed 1015, 2019.
   Google Scholar
• FDA issues draft guidance on naming biologicals. [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International Available from: www.gabionline.net/Guidelines/FDA-issues-draft-guidance-on-naming-biologicals. Accessed 1230, 2019.
   Google Scholar
• Australia reviewing plans for naming biosimilars. [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International Available from: www.gabionline.net/Guidelines/Australia-reviewing-plans-for-naming-biosimilars. Accessed 1230, 2019.
   Google Scholar
• Epstein MS, Ehrenpreis ED, Kulkarni PM. FDA-Related Matters Committee of the American College of Gastroenterology. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 2014;109:1856–1859.24957160
   PubMed Web of Science ®Google Scholar